组蛋白甲基转移酶G9a通过表观遗传沉默抑癌基因RARRES3促进肝癌发生
研究显示G9a组蛋白甲基转移酶在人类肝细胞癌中频繁上调,与肝癌进展及侵袭性临床病理特征显著相关。机制上,6p21染色体拷贝数增加和miR-1缺失导致G9a上调,G9a通过表观遗传沉默抑癌基因RARRES3发挥促癌作用。靶向G9a可能是肝细胞癌治疗的新方法。
要点
- G9a在人类肝细胞癌中频繁上调,与肝癌进展和侵袭性临床病理特征显著相关。
- G9a通过表观遗传沉默抑癌基因RARRES3发挥促癌功能。
- 靶向G9a可能是肝细胞癌治疗的新方法。
核心结论
- 本研究显示miR-1/G9a/RARRES3轴在肝癌发生中频繁失调,突显G9a的病理意义及其在肝细胞癌治疗中的治疗潜力。
研究设计与样本
- 通过RNA-Seq和qRT-PCR检测基因表达,利用慢病毒shRNA和CRISPR/Cas9基因编辑系统建立G9a敲低和敲除细胞系,在肝细胞癌细胞系和裸鼠模型中研究G9a的促瘤功能,通过RNA-Seq和ChIP实验鉴定下游靶点,并在体外和体内评估G9a抑制剂的治疗价值。
主要发现
- G9a在人类肝细胞癌中频繁上调,其上调与肝癌进展和侵袭性临床病理特征显著相关。
- 通过RNAi敲低、CRISPR/Cas9敲除和药理抑制使G9a失活,可显著消除H3K9二甲基化,并在体外和体内模型中抑制肝细胞癌细胞增殖和转移。
- 人类肝细胞癌中G9a频繁上调归因于染色体6p21的基因拷贝数增加,miR-1被鉴定为G9a的负调控因子,miR-1缺失解除对G9a的转录后抑制并促进其上调。
- 通过RNA测序鉴定抑癌基因RARRES3为G9a的关键靶点,RARRES3的表观遗传沉默促进G9a的促瘤功能。
临床怎么用
- 作者认为靶向G9a可能是肝细胞癌治疗的新方法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a major leading cause of cancer mortality worldwide. Epigenetic deregulation is a common trait of human HCC. G9s is an important epigenetics regulator however, its role in liver carcinogenesis remains to be investigated. METHODS: Gene expressions were determined by RNA-Seq and qRT-PCR. G9a knockdown and knockout cell lines were established by lentiviral-based shRNA and CRISPR/Cas9 gene editing system. Tumor-promoting functions of G9a was studied in both HCC cell lines and nude mice model. The downstream targets of G9a were identified by RNA-Seq and confirmed by ChIP assay. The therapeutic value of G9a inhibitors was evaluated both in vitro and in vivo. RESULTS: We identified G9a as a frequently upregulated histone methyltransferase in human HCCs. Upregulation of G9a was significantly associated with HCC progression and aggressive clinicopathological features. Functionally, we demonstrated that inactivation of G9a by RNAi knockdown, CRISPR/Cas9 knockout, and pharmacological inhibition remarkably abolished H3K9 di-methylation and suppressed HCC cell proliferation and metastasis in both in vitro and in vivo models. Mechanistically, we showed that the frequent upregulation of G9a in human HCCs was attributed to gene copy number gain at chromosome 6p21. In addition, we identified miR-1 as a negative regulator of G9a. Loss of miR-1 relieved the post-transcriptional repression on G9a and contributed to its upregulation in human HCC. Utilizing RNA sequencing, we identified the tumor suppressor RARRES3 as a critical target of G9a. Epigenetic silencing of RARRES3 contributed to the tumor-promoting function of G9a. CONCLUSION: This study shows a frequent deregulation of miR-1/G9a/RARRES3 axis in liver carcinogenesis, highlighting the pathological significance of G9a and its therapeutic potential in HCC treatment. Lay summary: In this study, we identified G9a histone methyltransferase was frequently upregulated in human HCC and contributes to epigenetic silencing of tumor suppressor gene RARRES3 in liver cancer. Targeting G9a may be a novel approach for HCC treatment.
引用
- Wei L, Chiu DK, Tsang FH, et al. Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3. J Hepatol. 2017. PMID: 28532996. doi:10.1016/j.jhep.2017.05.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。